No major side effects have been reported in HASPIN-deficient mice, or in preclinical studies of HASPIN inhibitors, suggesting that small-molecule compounds targeting HASPIN may be promising candidates for cancer therapy [12]. This evidence concerns the gene HASPIN and cancer.